Challenged by the findings of Hojo et al., we assessed whether the observed effect of CsA was dependent on CsA dose or CsA treatment duration, and how the observed incidence of cancer in our study ...

Cyclosporin H boosts a new lentivirus-delivered gene therapy with enhanced anti-sickling properties in blood stem cells from ...

Researchers described a promising new approach for using gene therapy to treat sickle cell disease in the journal Human Gene ...

Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major ...

Adding a 4-week course of cyclosporine to antiretroviral therapy did not improve immunologic or virologic response. During acute and early HIV infection, high levels of viremia generate a massive ...

Twelve medications with previously unreported or unconfirmed pharmacokinetic interactions with cyclosporine were identified as interacting by using routine data on cyclosporine pharmacokinetics ...